Gregory Ferreira
Pulmonary Disease · Sarasota, FLNPI 1790717908
Payments from drug & device makers
Across 446 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$914
- Novo Nordisk$739
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$502
- Actelion Pharmaceuticals US, Inc.$471
- Pfizer$468
- Takeda Pharmaceuticals U.S.A., Inc.$449
- plus $5K from 53 others
What the payments were for
- Food & beverage$8,52599%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,611 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 12 | $213,983 |
| EliquisApixaban | 151 | $170,171 |
| OpsumitMacitentan | 13 | $164,161 |
| MounjaroTirzepatide | 126 | $150,701 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $121,864 |
| OzempicSemaglutide | 92 | $98,874 |
| EntrestoSacubitril/Valsartan | 30 | $38,308 |
| Repatha SureclickEvolocumab | 32 | $37,590 |
| FarxigaDapagliflozin Propanediol | 50 | $35,587 |
| JardianceEmpagliflozin | 25 | $30,308 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $30,135 |
| JanuviaSitagliptin Phosphate | 28 | $26,929 |
| XareltoRivaroxaban | 19 | $24,894 |
| UbrelvyUbrogepant | 14 | $21,690 |
| Praluent PenAlirocumab | 25 | $18,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Farxiga, Brilinta | $218 | $255,91476 claims |
| PfizerEliquis, Paxlovid | $468 | $173,029164 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $471 | $164,16113 claims |
| Lilly USA, LLCMounjaro | $372 | $150,701126 claims |
| Novo NordiskOzempic | $739 | $98,87492 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $305 | $44,43540 claims |
| NovartisEntresto | $274 | $38,30830 claims |
| GSKBreo Ellipta, Incruse Ellipta | $327 | $34,92256 claims |
| AbbVieUbrelvy, Synthroid, Lumigan | $138 | $33,576103 claims |
| MerckJanuvia | $132 | $26,92928 claims |
| Johnson & JohnsonXarelto | $140 | $24,89419 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $17,15324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Sarasota
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.